Breaking News

€70M Investment by Chanelle Group

February 11, 2016

175 new jobs to be created in Loughrea over next five years as the firm doubles production capacity

Ireland’s largest indigenous pharmaceuticals manufacturer, Chanelle Group, has unveiled plans for the creation of 175 new jobs. The company is undertaking a €70 million investment program that will see Chanelle expand manufacturing capacity at its Loughrea headquarters and invest in R&D. Founded in 1985, Chanelle Group currently employs 375 people in Ireland, the UK, Jordan and India.

“In the past five years revenue has grown 100% and employment has increased by over 200 people,” said Michael Burke, founder and managing director, Chanelle Group said. “This growth has been driven by research and development of new products and the expansion into new markets. We invest over €8million annually in research and development and this investment will continue.”

Chanelle says it plans to launch 75 new products over the next five years in both human and veterinary products.

“Today’s investment program will double production capacity at our Loughrea manufacturing facility to ensure we can meet the global demand for both our market leading pharmaceuticals and the new products in development,” said Mr. Burke.

He also said that Chanelle Group will be expanding into new markets including the U.S., Central and South America, and expects revenues to increase by 65% over the next five years.

Construction on the expansion of production facilities will add 30,000 square feet of manufacturing plant space and will begin in March. 
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks